Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
BMJ Open Gastroenterol. 2022 Mar;9(1). doi: 10.1136/bmjgast-2022-000878.
There is a paucity of studies in the literature body evaluating short term outcomes following endoscopic retrograde cholangiopancreatography (ERCP) in patients with inoperable malignant hilar biliary obstruction (MHBO). We aimed to primarily evaluate 30-day mortality in these patients and secondarily, conduct a systematic review of studies reporting 30-day mortality.
We conducted a retrospective analysis of all patients with inoperable MHBO who underwent ERCP at Leeds Teaching Hospitals NHS Trust between February 2015 and September 2020. Logistic regression models constructed from baseline patient data, the modified Glasgow Prognostic Score (mGPS) and Charlson Comorbidity Index (CCI) were evaluated as predictors of 30-day mortality.
Eighty-seven patients (49 males) with a mean age of 70.4 years (SD ±12.3) were included. Cholangiocarcinoma was the most common aetiology of MHBO affecting 35/87 (40.2%). Technical success was achieved in 72/87 (82.8%). The 30-day mortality rate was 25.3% (22/87), of which 16 were due to progression of underlying malignant disease. On multivariate analysis, only leucocytosis (OR 4.12, 95% CI 2.70 to 7.41, p=0.02) was an independent predictor of 30-day mortality. Neither mGPS (p=0.47) nor CCI with a cut-off value of ≥7 (p=0.06) were significant predictors of 30-day mortality.
We demonstrated that 30-day mortality following ERCP for inoperable MHBO remains high despite technical success. Further studies are warranted to identify patients most appropriate for intervention.
目前文献中评估无法手术的恶性肝门胆管梗阻(MHBO)患者行内镜逆行胰胆管造影(ERCP)后短期结局的研究较少。我们旨在主要评估这些患者的 30 天死亡率,并对报告 30 天死亡率的研究进行系统回顾。
我们对 2015 年 2 月至 2020 年 9 月在利兹教学医院 NHS 信托基金接受 ERCP 治疗的所有无法手术的 MHBO 患者进行了回顾性分析。从基线患者数据、改良格拉斯哥预后评分(mGPS)和 Charlson 合并症指数(CCI)构建的逻辑回归模型被评估为 30 天死亡率的预测因素。
87 例(49 例男性)患者,平均年龄为 70.4 岁(标准差±12.3)。MHBO 的最常见病因是胆管癌,影响 35/87(40.2%)例患者。72/87(82.8%)例患者获得技术成功。30 天死亡率为 25.3%(22/87),其中 16 例死于基础恶性疾病进展。多变量分析显示,只有白细胞增多症(OR 4.12,95%CI 2.70 至 7.41,p=0.02)是 30 天死亡率的独立预测因素。mGPS(p=0.47)和 CCI 截断值≥7(p=0.06)均不是 30 天死亡率的显著预测因素。
我们发现,尽管技术成功,但无法手术的 MHBO 患者行 ERCP 后 30 天死亡率仍然很高。需要进一步的研究来确定最适合干预的患者。